InvestSMART

PharmAust Limited (ASX: PAA) - Announcements

Current share price for PAA : $0.230 0.015 (6.98%)+

ASX company news and announcements for PharmAust Limited (PAA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PharmAust Limited (PAA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PharmAust Limited (PAA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PharmAust Limited (PAA)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- PharmAust Initiates Combination Therapy Evaluations in Dogs 17 Jun 2015 8:27AM $0.010 $0.230 risen by 2,200%
- Change of registry address 12 Jun 2015 6:33PM $0.009 $0.230 risen by 2,455.56%
- Change of Share Registry Address 12 Jun 2015 11:25AM $0.010 $0.230 risen by 2,200%
- Appendix 3B & s708 Notice 2 Jun 2015 3:33PM $0.011 $0.230 risen by 1,990.91%
- Results of Meeting 26 May 2015 1:10PM $0.012 $0.230 risen by 1,816.67%
- EGM Shareholder Presentation 26 May 2015 9:49AM $0.012 $0.230 risen by 1,816.67%
- Second Dog Shows Suppression of Cancer Marker at Days 3 & 7 19 May 2015 8:29AM $0.012 $0.230 risen by 1,816.67%
- Reduction of further Cancer Marker confirmed in Human Trial 11 May 2015 8:24AM $0.012 $0.230 risen by 1,816.67%
- First Dog Shows Suppression of Cancer Marker 1 May 2015 8:28AM $0.010 $0.230 risen by 2,200%
- Appendix 4C Quarterly Report & Company Update 22 Apr 2015 8:29AM $0.011 $0.230 risen by 1,990.91%
- Notice of General Meeting/Proxy Form 21 Apr 2015 4:04PM $0.011 $0.230 risen by 1,990.91%
- Approval of Dose Escalation of PPL-1 in Human Trial 15 Apr 2015 8:24AM $0.012 $0.230 risen by 1,816.67%
- Modification of Clinical Trial in Dogs 13 Apr 2015 8:26AM $0.013 $0.230 risen by 1,669.23%
- Lyell McEwin Hospital approved to join PharmAust trial 8 Apr 2015 8:26AM $0.014 $0.230 risen by 1,542.86%
- Joint Patent with Japanese Corporation now published 31 Mar 2015 10:12AM $0.011 $0.230 risen by 1,990.91%
- Final Patient in Cohort Demonstrates Tumour Marker Reduction 24 Mar 2015 8:26AM $0.010 $0.230 risen by 2,200%
- Completion of Lowest Dose Cohort in Human Cancer Trial 17 Mar 2015 8:20AM $0.010 $0.230 risen by 2,200%
- PharmAust completes $3.14m Share Placement oversubscribed 16 Mar 2015 9:06AM $0.010 $0.230 risen by 2,200%
- Trading Halt 12 Mar 2015 9:44AM $0.009 $0.230 risen by 2,455.56%
- Second Cancer Patient Completes Course With Stable Disease 5 Mar 2015 8:26AM $0.008 $0.230 risen by 2,775%
- Appendix 4D and Half Yearly Report & Accounts 26 Feb 2015 3:39PM n/a $0.230 n/a
- Further Update on New Anti-Cancer Drug PPL-1 in Human Trial 24 Feb 2015 8:25AM $0.008 $0.230 risen by 2,775%
- Human Trial Prelim Results Shows Reduction in Tumour Markers 9 Feb 2015 8:27AM $0.006 $0.230 risen by 3,733.33%
- Appendix 4C - Quarterly Report & Company Update 30 Jan 2015 8:18AM n/a $0.230 n/a
- Shareholder Update - Human & Canine Trials 20 Jan 2015 8:25AM $0.007 $0.230 risen by 3,185.71%

601 - 625 of 796 results

Page 25 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.